Episode 1: Exploring Psychedelics in Psychiatric Treatment with Professor Roger McIntyre https://PsychopharmToday.podbean.com In this inaugural episode of Psychopharm Today, host Dr. Josh Rosenblat sits down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment. Dr. Rosenblat is psychiatrist, associate professor, and clinician researcher at the University of Toronto. His research focus is clinical trials of novel psychopharmacological interventions for mood disorders and symptoms that do not respond fully to available treatments. His current research includes trials involving Ketamine and Psilocybin. Dr. McIntyre is a psychiatrist and Fellow of The Royal College of Physicians of Canada. He is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Since 2014, he has been repeatedly named by Clarivate Analytics as one of “The World’s Most Influential Scientific Minds,” and just last year, he was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Foundation. Dr. McIntyre’s research has aimed to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. He has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre has also been extensively involved in medical education and has received numerous teaching awards, and has contributed significantly to clinical practice guidelines. He is the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in mood disorders. Psychopharm Today is brought to you by the ASCP Technology Committee Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine Hosted by Joshua Rosenblat, M.D., University of Toronto Other Committee Members: Rajiv Radhakrishnan, M.D., Yale School of Medicine, Chair Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry, Co-Chair Stefano Comai, Ph.D., Pharm.D., University of Padua Michael Henry, M.D., Massachusetts General Hospital Bashkim Kadriu, M.D., FAPA, Jazz Pharmaceuticals, Inc. Matthew Macaluso, D.O., The University of Alabama At Birmingham Nivedita Nadkarni, M.D., Essentia health Andrew Olagunju, M.D., M.Sc., Ph.D., McMaster University Daniel Umbricht, M.D., Xperimed GmbH Join us as we explore the latest in psychopharmacology, featuring expert insights and innovative discussions from leaders in the field. Fri, 20 Feb 2026 10:20:32 -0500 https://podbean.com/?v=5.5 en Copyright 2025 All rights reserved. Science 1440 episodic The American Society of Clinical Psychopharmacology The American Society of Clinical Psychopharmacology No false https://feed.podbean.com/PsychopharmToday/feed.xml https://pbcdn1.podbean.com/imglogo/image-logo/19456266/Untitled_design_6_copy3agd5h.png Episode 1: Exploring Psychedelics in Psychiatric Treatment with Professor Roger McIntyre https://PsychopharmToday.podbean.com 144 144 Episode 2: Exploring a New Era in Schizophrenia Treatment with Drs. Steven Paul and Christoph Correll Episode 2: Exploring a New Era in Schizophrenia Treatment with Drs. Steven Paul and Christoph Correll https://PsychopharmToday.podbean.com/e/interview-with-drs-steve-paul-and-christoph-correll/ https://PsychopharmToday.podbean.com/e/interview-with-drs-steve-paul-and-christoph-correll/#comments Fri, 20 Feb 2026 10:20:32 -0500 PsychopharmToday.podbean.com/364412a8-fe05-3b66-bcfd-a7b954121f75 This episode of Psychopharm Today features a discussion on the evolution of schizophrenia treatment, specifically focusing on the recent FDA approval of Cobenfy. Experts Dr. Steven Paul and Dr. Christoph Correll explain how this new medication represents a shift away from traditional dopamine-blocking drugs toward muscarinic receptor agonists. The speakers highlight the drug's unique history, from its origins in Alzheimer's research to its ability to modulate presynaptic dopamine without typical side effects like weight gain or movement disorders. They also address the challenges of gastrointestinal side effects and the potential for these agents to improve cognitive and negative symptoms. Ultimately, research suggests that targeting cholinergic systems marks the beginning of a transformative new era in psychiatric pharmacotherapy.

 

Psychopharm Today is brought to you by the ASCP Technology Committee

Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health, NIH Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine Hosted by Daniel Umbricht, M.D., Xperimed GmbH

Other Committee Members:

  • Vishesh Agarwal, M.D., ChristianaCare
  • Ahmed Ahmed, M.D., Baylor College of Medicine
  • Andrea Boscutti, M.D., The University of Texas Health Science Center At Houston
  • Lawrence Cohen, B.A., Pharm.D., UNT System College of Pharmacy/ Regulatory Insurance Advisors
  • Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry
  • Nicholas Fabiano, M.D., The Ottawa Hospital
  • Michael Henry, M.D., Massachusetts General Hospital
  • Jenessa Johnston, Ph.D., National Institute of Mental Health, NIH
  • Bashkim Kadriu, M.D., FAPA, Bristol Meyers Squibb (BMS)
  • Rida Khan, M.D., Westchester Medical Center
  • Gonzalo Laje, M.D., WBMA, LLC
  • Jonathan Leung, Pharm.D., Mayo Clinic, Rochester, MN
  • Matthew Macaluso, D.O., The University of Alabama At Birmingham
  • Nivedita Nadkarni, M.D., Essentia health
  • Andrew Olagunju, M.D.,M.Sc.,Ph.D., McMaster University
  • Thulasi R Reddy, M.D., Creedmoor Psychiatric Center
]]> This episode of Psychopharm Today features a discussion on the evolution of schizophrenia treatment, specifically focusing on the recent FDA approval of Cobenfy. Experts Dr. Steven Paul and Dr. Christoph Correll explain how this new medication represents a shift away from traditional dopamine-blocking drugs toward muscarinic receptor agonists. The speakers highlight the drug's unique history, from its origins in Alzheimer's research to its ability to modulate presynaptic dopamine without typical side effects like weight gain or movement disorders. They also address the challenges of gastrointestinal side effects and the potential for these agents to improve cognitive and negative symptoms. Ultimately, research suggests that targeting cholinergic systems marks the beginning of a transformative new era in psychiatric pharmacotherapy.

 

Psychopharm Today is brought to you by the ASCP Technology Committee

Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health, NIH
Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine
Hosted by Daniel Umbricht, M.D., Xperimed GmbH

Other Committee Members:

  • Vishesh Agarwal, M.D., ChristianaCare
  • Ahmed Ahmed, M.D., Baylor College of Medicine
  • Andrea Boscutti, M.D., The University of Texas Health Science Center At Houston
  • Lawrence Cohen, B.A., Pharm.D., UNT System College of Pharmacy/ Regulatory Insurance Advisors
  • Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry
  • Nicholas Fabiano, M.D., The Ottawa Hospital
  • Michael Henry, M.D., Massachusetts General Hospital
  • Jenessa Johnston, Ph.D., National Institute of Mental Health, NIH
  • Bashkim Kadriu, M.D., FAPA, Bristol Meyers Squibb (BMS)
  • Rida Khan, M.D., Westchester Medical Center
  • Gonzalo Laje, M.D., WBMA, LLC
  • Jonathan Leung, Pharm.D., Mayo Clinic, Rochester, MN
  • Matthew Macaluso, D.O., The University of Alabama At Birmingham
  • Nivedita Nadkarni, M.D., Essentia health
  • Andrew Olagunju, M.D.,M.Sc.,Ph.D., McMaster University
  • Thulasi R Reddy, M.D., Creedmoor Psychiatric Center
]]> The American Society of Clinical Psychopharmacology false No 3297 2 full Episode 1: Exploring Psychedelics in Psychiatric Treatment with Professor Roger McIntyre Episode 1: Exploring Psychedelics in Psychiatric Treatment with Professor Roger McIntyre https://PsychopharmToday.podbean.com/e/episode-1-exploring-psychedelics-in-psychiatric-treatment-with-professor-roger-mcintyre/ https://PsychopharmToday.podbean.com/e/episode-1-exploring-psychedelics-in-psychiatric-treatment-with-professor-roger-mcintyre/#comments Mon, 03 Feb 2025 12:38:11 -0500 infornh.podbean.com/c362b114-67dd-3872-9519-9de594e03b36 In this inaugural episode of Psychopharm Today, host Dr. Josh Rosenblat sits down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment.

Dr. Rosenblat is psychiatrist, associate professor, and clinician researcher at the University of Toronto.  His research focus is clinical trials of novel psychopharmacological interventions for mood disorders and symptoms that do not respond fully to available treatments.  His current research includes trials involving Ketamine and Psilocybin. 

Dr. McIntyre  is a psychiatrist and Fellow of The Royal College of Physicians of Canada.  He is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Since 2014, he has been repeatedly named by Clarivate Analytics as one of “The World’s Most Influential Scientific Minds,” and just last year, he was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Foundation.  Dr. McIntyre's research has aimed to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders.  He has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. 

Dr. McIntyre has also been extensively involved in medical education and has received numerous teaching awards, and has contributed significantly to clinical practice guidelines.  He is the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in mood disorders.

----more----

Psychopharm Today is brought to you by the ASCP Technology Committee

Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine Hosted by Joshua Rosenblat, M.D., University of Toronto

Other Committee Members:

  • Rajiv Radhakrishnan, M.D., Yale School of Medicine, Chair
  • Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry, Co-Chair
  • Stefano Comai, Ph.D., Pharm.D., University of Padua
  • Michael Henry, M.D., Massachusetts General Hospital
  • Bashkim Kadriu, M.D., FAPA, Jazz Pharmaceuticals, Inc.
  • Matthew Macaluso, D.O., The University of Alabama At Birmingham
  • Nivedita Nadkarni, M.D., Essentia health
  • Andrew Olagunju, M.D., M.Sc., Ph.D., McMaster University
  • Daniel Umbricht, M.D., Xperimed GmbH

Join us as we explore the latest in psychopharmacology, featuring expert insights and innovative discussions from leaders in the field.

]]> In this inaugural episode of Psychopharm Today, host Dr. Josh Rosenblat sits down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment.

Dr. Rosenblat is psychiatrist, associate professor, and clinician researcher at the University of Toronto.  His research focus is clinical trials of novel psychopharmacological interventions for mood disorders and symptoms that do not respond fully to available treatments.  His current research includes trials involving Ketamine and Psilocybin. 

Dr. McIntyre  is a psychiatrist and Fellow of The Royal College of Physicians of Canada.  He is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Since 2014, he has been repeatedly named by Clarivate Analytics as one of “The World’s Most Influential Scientific Minds,” and just last year, he was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Foundation.  Dr. McIntyre's research has aimed to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders.  He has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. 

Dr. McIntyre has also been extensively involved in medical education and has received numerous teaching awards, and has contributed significantly to clinical practice guidelines.  He is the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in mood disorders.

----more----

Psychopharm Today is brought to you by the ASCP Technology Committee

Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health
Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine
Hosted by Joshua Rosenblat, M.D., University of Toronto

Other Committee Members:

  • Rajiv Radhakrishnan, M.D., Yale School of Medicine, Chair
  • Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry, Co-Chair
  • Stefano Comai, Ph.D., Pharm.D., University of Padua
  • Michael Henry, M.D., Massachusetts General Hospital
  • Bashkim Kadriu, M.D., FAPA, Jazz Pharmaceuticals, Inc.
  • Matthew Macaluso, D.O., The University of Alabama At Birmingham
  • Nivedita Nadkarni, M.D., Essentia health
  • Andrew Olagunju, M.D., M.Sc., Ph.D., McMaster University
  • Daniel Umbricht, M.D., Xperimed GmbH

Join us as we explore the latest in psychopharmacology, featuring expert insights and innovative discussions from leaders in the field.

]]> In this inaugural episode of Psychopharm Today, we sit down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment. Professor McIntyre shares insights into the latest studies exploring the use of substances like psilocybin and ketamine for conditions such as depression and PTSD. We dive into the science behind how these treatments work, ethical considerations, and the challenges researchers face in bringing these therapies into mainstream mental health care. Join us for a thought-provoking conversation that sheds light on the future of psychedelics in mental health. ASCP Technology Committee false No 3420 1 1 full